

STUDY PROTOCOL

Open Access

Using novel Canadian resources to improve medication reconciliation at discharge: study protocol for a randomized controlled trial

Robyn Tamblyn^{1,2,3*}, Allen R Huang^{2,3}, Ari N Meguerditchian^{2,3}, Nancy E Winslade^{2,3}, Christian Rochefort^{2,3}, Alan Forster⁴, Tewodros Eguale^{1,2}, David Buckeridge^{1,2}, André Jacques⁵, Kiyuri Naicker² and Kristen E Reidel²

Abstract

Background: Adverse drug events are responsible for up to 7% of all admissions to acute care hospitals. At least 58% of these are preventable, resulting from incomplete drug information, prescribing or dispensing errors, and overuse or underuse of medications. Effective implementation of medication reconciliation is considered essential to reduce preventable adverse drug events occurring at transitions between community and hospital care. An electronically enabled discharge reconciliation process represents an innovative approach to this problem.

Methods/Design: Participants will be recruited in Quebec and are eligible for inclusion if they are using prescription medication at admission, covered by the Quebec drug insurance plan, admitted from the community, 18 years or older, admitted to a general or intensive care medical or surgical unit, and discharged alive. A sample size of 3,714 will be required to detect a 5% reduction in adverse drug events. The intervention will comprise electronic retrieval of the community drug list, combined with an electronic discharge reconciliation module and an electronic discharge communication module. The primary outcomes will be adverse drug events occurring 30 days post-discharge, identified by a combination of patient self-report and chart abstraction. All emergency room visits and hospital readmission during this period will be measured as secondary outcomes. A cluster randomization approach will be used to allocate 16 medical and 10 surgical units to electronic discharge reconciliation and communication versus usual care. An intention-to-treat approach will be used to analyse data. Logistic regression will be undertaken within a generalized estimating equation framework to account for clustering within units.

Discussion: The goal of this prospective trial is to determine if electronically enabled discharge reconciliation will reduce the risk of adverse drug events, emergency room visits and readmissions 30 days post-discharge compared with usual care. We expect that this intervention will improve adherence to medication reconciliation at discharge, the accuracy of the community-based drug history and effective communication of hospital-based treatment changes to community care providers. The results may support policy-directed investments in computerizing and training of hospital staff, generate key requirements for future hospital accreditation standards, and highlight functional requirements for software vendors.

Trial registration: NCT01179867

Keywords: Adverse events, Medication reconciliation, Transitions in care

* Correspondence: robyn.tamblyn@mcgill.ca

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada

²Clinical and Health Informatics Research Group, McGill University, 1140 Pine Avenue West, Montreal, QC H3A 1A3, Canada

Full list of author information is available at the end of the article

Background

Up to 7% of admissions to acute care hospitals are related to adverse drug events (ADEs) [1]. ADEs are the sixth leading cause of death [2] at a cost over \$5.6 million (USD) per hospital per year [3]. An estimated 19% to 23% of inpatients will have an adverse event within 30 days of hospital discharge [4,5], 14.3% will be re-admitted [6], and 70% of these events will be related to prescription medication [4,5]. Fortunately, at least 58% of these ADEs are preventable, resulting from incomplete drug information, prescribing or dispensing errors, and overuse or underuse of medications [7,8]. Reconciliation of changes to medications that occur during hospitalization with community-based prescriptions is believed to be important to reduce the risk of preventable ADEs during transitions in care. Indeed, one recent study suggests that inadvertent discrepancies in community and hospital medications may increase the risk of adverse events [9]. Hospitals in Canada and the United States now require implementation of medication reconciliation for accreditation [10-13]. Discharge reconciliation has been given the highest priority because it is expected to reduce the risk of adverse events caused by failures to reconcile the community drug regimen with changes made in drugs and doses during the hospital stay. It will also communicate information about medication changes to the responsible community-based pharmacists and physicians at discharge. Despite its importance, there are considerable challenges to widespread implementation [14-31].

Challenge 1. Obtaining an accurate community-based medication list

Difficulty in obtaining accurate information about the community-based drug list is one of the greatest challenges in medication reconciliation [32]. In a recent survey of hospital staff, respondents estimated that 87% of admitted patients did not know which medications they took, 80% of the time medication information was not available from alternate sources such as relatives or community-based care providers, and in 63% of admissions, hospital staff were unable to access community-based records [32]. As a result, 46% to 67% of unintended discrepancies in medication reconciliation are omitted medications, that is medications that were taken in the community but were neither prescribed at admission nor reconciled at discharge [16,28,29,33-36]. The most commonly omitted medications are cardiovascular drugs, pain medications, anti-infectious medications, and central nervous system medications such as antidepressants and sleeping pills [37]. Overall, 23% to 37% of unintended discrepancies between community and hospital medication are considered clinically significant, meaning that there is substantial potential to cause harm [16,28,29,33-36].

An increasing number of hospitals are employing pharmacists in the emergency department and inpatient units to obtain a complete history of community-based medications [10-12,16-18,20,38-44]. Pharmacists have been shown to be more effective than nurses or medical staff in obtaining an accurate medication history, reducing errors from 323 to 86 per 1,000 prescription orders, compared with nurse-taken histories where errors were reduced to only 157 per 1,000 [37]. The superiority of pharmacists in medication history-taking may be related to two aspects of care. First, pharmacists spend an average of 12.9 minutes per patient to take a community-based medication history, two to three times longer than medical or nursing staff [45]. Second, pharmacists dispense medication and in general are much more knowledgeable about medication characteristics. This expertise may be particularly useful when patients are attempting to recall their medication, as most patients remember their medications by the colour, shape and general purpose of the pill [27,46]. Pharmacists may be more likely to identify these medications than medical and nursing staff, who know the name but not usually the colour and shape of the pill. Indeed, a recent pilot study performed in a US Veterans Affairs hospital found that the integration of pill image files with medication lists was a useful approach to verify current use with patients [27].

Although pharmacist deployment in clinical care areas is considered a cost-effective investment in preventing medication errors [47], pharmacists are conventionally not available on weekends, evenings and nights, nor are community-based pharmacies or office-based practices usually open to transmit information about community-based medications by fax or telephone. As such, recent research has shown that unintended errors in reconciling community and admission medications at discharge are more likely to occur on night-time admission, particularly for elderly patients and those using more than four medications [26].

New initiatives have been undertaken to use electronic medical records to access information about the community drug profile [29-31,48]. Brigham and Women's Hospital in Boston has shown that retrieval from electronic medical records can identify 65% of current medications [30]. The major limitations of using medication lists in electronic medical records is that many of the listed medications (up to 70%) are no longer being used by the patient as medication lists become out-of-date, and 15.5% of current medications are not listed in the electronic medical record [48]. In contrast, almost all pharmacies have been computerized so that they can manage the online adjudication processes of public and private drug insurance programs [49]. Prior research has shown that records of dispensed prescriptions can be

used to accurately measure medication adherence [50-52]. A recent study from the Netherlands also suggests that community pharmacy records can identify up to 97.6% of community-based medications accurately [29]. Although it represents a promising approach, the utility of community-based pharmacy records for medication reconciliation at hospital discharge has not been formally assessed.

Challenge 2. Ensuring medication reconciliation is conducted for all patients at risk

In compliance with accreditation standards, most hospitals have instituted a paper-based medication reconciliation process. However, adherence is poor, with medication reconciliation generally conducted in less than 20% of patients at risk [10-12,16-18,20,38-44]. This low rate of utilization persists even when staff workload is reduced by an electronic 'copy and paste' process that eliminates the need to first document the community-based medication list and then re-transcribe the list for the hospital medication order [26,53]. One of the main barriers is the time and resources required for data collection (community drug list determination), particularly in emergency departments (ED), where most patients are admitted. For a typical ED with 50,000 visits per year, it is estimated that an additional 2,900 hours of nursing time and 8,750 hours of pharmacist time would be required (an added cost of \$349,500 at \$30/hour) to complete the admission medication reconciliation for the 35% of patient visits where it is required [54]. Moreover, 20% of patients die or are discharged before complete information can be obtained about the community drug list [54].

Overcoming inefficiencies in obtaining the community drug list appears to be essential to improve adherence. For example, when Brigham and Women's Hospital established a prototype medication reconciliation module that integrated data from the ambulatory electronic medical record and discharge medication orders, they improved adherence to 68.7%, as the majority of physicians could reduce the time to complete the process by 10 minutes. Even higher rates of adherence - from 20% to 90% at admission and 95% at discharge - were achieved at Bellevue Hospital in New York, when admission and discharge orders were blocked until the medication reconciliation module was completed [53]. However, this option is only possible in hospitals that have successfully implemented computerized prescriber order entry, which represents less than 20% of hospitals in the United States and even fewer in Canada [55-57].

Challenge 3. Communicating drug or dose changes at discharge to community-based prescribing physicians and dispensing pharmacists

A substantial proportion of ADEs occur in hospitalized patients shortly after discharge [4,5]. It is estimated that

72% of medication reconciliation errors at discharge are due to an incomplete preadmission community drug list, while 26% are due to failures in reconciling the medication history or changes made during the hospital stay with discharge orders [36]. During hospitalization, 31% of patients will have changes made in the dose and frequency of medication, 9% will have a medication added or substituted and 4.1% to 8% will have a medication stopped [36,58]. At the present time, there is no timely and effective mechanism of communicating these changes in medication to the community-based prescribing physician(s) and dispensing pharmacist(s). Most patients fill their discharge medication prescription within the first few days after hospital discharge [59], long before the discharge summary that summarizes the reasons for hospitalization and changes in medical management has been dictated or transmitted. Indeed, in the majority of admissions, the community-based care team does not receive critical information on the patient's health status and modified treatment plan post-discharge [60]. As a result, the patient's community-based pharmacist needs to determine whether remaining refills on community-based drugs are to be added to the discharge prescription or stopped; and whether the dose prescribed on a discharge medication is to be added or replace the existing preadmission medication dose. As the community-based profile is typically incomplete, these issues are usually not addressed in the discharge prescription. To add to the challenges of discharge reconciliation, 70% of elderly patients who use many medications are under the care of a number of prescribing physicians and over 40% of patients will use more than one dispensing pharmacy [61,62]. For all of these reasons, it is not surprising that 17% to 21% of patients will experience ADEs post-discharge, and that the majority of discrepancies in community and hospital medication reconciliation are related to therapeutic duplication (more than one drug from the same class), dose errors, and omitted medication [7,36,63,64].

In summary, effective implementation of medication reconciliation is essential to reduce preventable ADEs occurring at the transitions between community and hospital care. More efficient methods of obtaining the community drug list, an automated order entry process that facilitates re-ordering of hospital- and community-based medications at discharge, and more efficient means of transmitting discontinuation and change orders to community-based pharmacists and physicians are needed.

Study objective

To determine if an electronically enabled discharge reconciliation intervention that includes electronic retrieval of community drug lists from community pharmacy records; reconciliation of community and hospital drugs

at discharge; and communication of treatment changes to the community-based prescribing physicians and pharmacists will reduce the risk of ADEs, ED visits and readmissions in the 30 days post-discharge compared with usual care.

Pilot study results

To determine if the electronic retrieval of the community drug list would add value to the usual care process, we conducted a pilot study at the McGill University Health Centre. We used an integrated drug management system (MOXXI) developed previously by our research group to provide online access to the Quebec government prescription database, which includes all medications prescribed by community pharmacies [57,62,65-69]. The MOXXI system provides near real-time information (within 24 hours) on dispensed prescriptions from the 1,800 community pharmacies in Quebec, through a secure virtual private network. This network is linked to the prescription claims system of the government insurer (RAMQ). In this pilot study, we assessed whether the community drug profile was able to identify missing medication at admission; the perceived value of electronic retrieval for the treatment team; and the number of community providers who would be affected by a discharge reconciliation and communication intervention. In 91 consecutive patients admitted in 2008, we showed that electronically retrieved community pharmacy records identified, on average, three additional drugs per patient. For 21% of patients, five or more drugs were identified. Over 90% of physicians and nurses who accessed real-time community pharmacy records believed this information improved the quality and continuity of care. Overall, 72.7% were confident in their ability to use a computer to gain access (even though 29% had limited or no prior computer experience). Access to the community drug profile reduced medication history-taking by 2.5 minutes per patient. Moreover, the challenges for staff in accessing treatment information for traditional medication reconciliation were substantial: 31% of patients had more than one dispensing pharmacy, most had multiple prescribing physicians, and 14.3% had more than eight (Table 1).

Methods/Design

Trial design

A randomized cluster design will be used to determine if electronically enabled discharge reconciliation reduces adverse events post-discharge. The study will be conducted at the McGill University Health Centre, a network of teaching hospitals that serves a population of 1.3 million. The study population will be patients admitted to medical and surgical units. Patients will be stratified by type of unit, and a cluster randomization approach will be used to allocate the 16 medical and 10 surgical units to discharge reconciliation and communication versus usual care (Figure 1). A cluster randomization approach is required to avoid contamination between the two interventions (usual care versus discharge reconciliation and communication). This is because all medical staff clustered within units will be trained and provided with onsite support to successfully use computerized order entry for community and inpatient drug reconciliation. It will not be possible to randomize patients within a unit without risk of contamination.

Participants

Patients will be eligible for inclusion if they are using prescription medication at admission, covered by the Quebec drug insurance plan (50% of the population and 100% of persons 65 years of age and older), admitted from the community, 18 years or older at admission, admitted to a general medical or surgical unit or intensive care, and discharged alive. Patients who are cognitively impaired or otherwise unable to provide consent will be included as we have shown that this subpopulation of patients may be at greatest risk of adverse events because of communication problems [70]. Tri-council ethics guidelines deem that this subpopulation should not be excluded from interventions that potentially provide direct benefit to the participant due to the inability to provide informed consent (Article 4.5) [71]. For these patients, the family or medical director of the admitting unit will authorize study participation. Patients who may not be able to consent at the time of admission because they are cognitively impaired or unable to communicate will be followed up by a researcher to determine if the

Table 1 The number of prescribing physicians and dispensing pharmacies for 91 consecutive patients admitted to the McGill University Health Centre (April-May, 2008)

Number of prescribing physicians	N (%)	Number of dispensing pharmacies	N (%)
One	6 (6.6%)	One	60 (69.0%)
Two to four	34 (37.4%)	Two	18 (20.7%)
Five to eight	38 (41.8%)	Three or more	9 (10.4%)
Nine or more	13 (14.3%)		




Figure 1 Stratified random cluster design of electronically enabled discharge reconciliation versus usual care.

patient is able to provide an informed consent. At that time, patients who are able to provide informed consent and choose not to will be excluded from the study.

Demographic, clinical and health care service use characteristics of the study population will be retrieved from the admission note. Data from provincial administrative databases in the year before admission and the two months after discharge will be used to characterize the study population, assess readmission, evaluate the integrity of randomization, and assess potential biases related to attrition [72,73].

Intervention

Usual care

The community drug list is generally documented at the time of admission. For patients admitted through the ED, the triage nurse and ED pharmacist (weekdays only) are responsible for documenting the community medication list in the chart. This may be reviewed and updated by the admitting physician, resident and nurse. When the patient is admitted directly to the unit, the admitting nurse and staff physician or resident are responsible for documenting the medication history. In addition, there are 14 full-time equivalent pharmacists available on weekdays to provide inpatient clinical pharmacy service support for the medical and surgical units, including intensive care. Unit-based pharmacists may provide assistance in obtaining the community drug history, particularly for more complex medication regimens.

At discharge, the attending physician or resident uses the list of current hospital medication, with or without the community drug list (if available), to prescribe the discharge medication. Similar to other hospitals, the McGill University Health Centre has implemented an electronic health record (OACIS) that integrates all relevant clinical information from the hospital pharmacy, laboratory, diagnostic imaging and consultation reports to be viewed by the treatment team. Active hospital medications can be viewed by accessing the patient's electronic OACIS record,

the medication administration chart or nurse's kardex. The patient is provided with a written discharge prescription to fill at their community pharmacy, and may or may not receive verbal or written instructions about new medications or community medications. If the community pharmacist has questions about whether they should continue pre-existing medications that are not included in the discharge medication, they ask the patient, and may call the physician or discharging unit of the hospital.

Electronically enabled discharge reconciliation and communication

The experimental intervention has three components. First, at admission, the community drug list will be electronically retrieved from the RAMQ using the MOXXI real-time interface, and transferred to the hospital pharmacy system (Figure 2). In a prior validation study, we have shown that RAMQ prescription claims achieve an accuracy of 100% for the drug dispensed, and 98.5% for the date of dispensing [72]. We will include all drugs where the patient has an active supply of medication in the two months prior to admission, as well as provide the treatment team with the option of reviewing all drugs dispensed in the past six months using the MOXXI drug profile. The admitting team and hospital pharmacist will verify the list with the patient, add any other medications including over-the-counter and herbal products, and the resulting list will be used to pre-populate the discharge module (Figure 3). Second, at discharge, the attending physician or resident will write the discharge prescription using the discharge reconciliation module. The discharge reconciliation module will be integrated and directly accessible through the patient's electronic OACIS record. It will display the current active hospital medications, and the verified community-based drug list, sorted by therapeutic class (for example, antihypertensives, antidepressants) to facilitate reconciliation (Figure 3). The attending physician or resident will 'click' on each of the hospital medications




Figure 2 MOXXI drug profile: medication active today (vertical line) and medication history (six months).

that should be included in the discharge prescription, and add any medications from the community drug list that should be continued. All community-based medications that are not included in the discharge prescription will be transferred to the discontinuation section to be verified by

the discharging physician. To assist in viewing the results of the reconciliation process, new medication and dose changes will be separated from discontinued medication. Third, the discharge communication module (Figure 4) will facilitate the identification and transfer of information

In Hospital List

- ☒ Atorvastatin 20mg PO qHS
- ☒ Perindopril 2mg PO qAM
- ☒ NTG spray 0.4mg S/L PRN
- ☒ Clopidrogel 75mg PO qD
- ☒ ECASA 81mg PO qD
- ☐ Heparin 5000U S/C q12h
- ☒ Cal-D 1 PO bid
- ☒ Hydrochlorothiazide 12.5mg PO qD
- ☒ Glucalide 40mg PO bid
- ☒ Levthyroxine 0.1mg PO qD
- ☐ Salbutamol 1 neb aerosol q6h PRN
- ☒ Ibuprofen 200mg PO tid
- ☐ Codeine 30mg PO q4h PRN
- ☒ Lorazepam 0.5mg PO qHS PRN
- ☒ Salinex 2 spray qid PRN
- ☒ Vitamin B12 100mcg IM qMonth
- ☒ Risedronate 35mg PO qSundays

Community List

- ☒ Atorvastatin 10mg PO qHS
- ☒ Bisoprolol 5mg PO bid
- ☐ Lisinopril 20mg PO qd
- ☒ NTG spray 0.4mg S/L PRN
- ☒ ASA 81mg PO qD
- ☒ Calcium+Vitamin-D 1 PO bid
- ☒ Hydrochlorothiazide 25mg PO qD
- ☐ Glimepiride 5mg PO qD
- ☐ Metformin 850mg PO tid with meals
- ☐ Rosiglitazone 8mg PO qAM
- ☒ Levthyroxine 0.1mg PO qD
- ☒ Lorazepam 1mg PO qHS
- ☐ Diclofenac 1.5% to Right knee bid
- ☐ Omeprazole 20mg PO qD
- ☒ Salt-water-desalinated
- ☒ Mometasone 50mcg Nasal spray 2 sprays qD
- ☒ Vitamin B12 100mcg IM qMonth

Discharge Rx

Prescribed

- Bisoprolol 5mg PO bid
- Cal-D 1 PO bid
- Clopidrogel 75mg PO qD
- ECASA 81mg PO qD
- Glucalide 40mg PO bid
- Ibuprofen 200mg PO tid
- Levthyroxine 0.1mg PO qD
- Mometasone 50mcg Nasal spray 2 sprays qD
- NTG spray 0.4mg S/L PRN
- Perindopril 2mg PO qAM
- Risedronate 35mg PO qSundays
- Salinex 2 spray qid PRN
- Tylenol 500mg bid PRN
- Vitamin B12 100mcg IM qMonth

Dose changes

- Atorvastatin 20mg PO qHS
- Hydrochlorothiazide 12.5mg PO qD
- Lorazepam 0.5mg PO qHS PRN

Discontinued

- Codeine 30mg PO q4h PRN
- Diclofenac 1.5% to Right knee bid
- Glimepiride 5mg PO qD
- Heparin 5000U S/C q12h
- Lisinopril 20mg PO qD
- Metformin 850mg PO tid with meals
- Omeprazole 20mg PO qD
- Rosiglitazone 8mg PO qAM

Figure 3 Discharge reconciliation and prescription module.

on discontinued and changed medication to the respective dispensing pharmacy or pharmacies and prescribing physician(s) along with the reasons for these changes. The attending physician or resident will document the reason for discontinuing or changing the dose of each medication using a drop-down menu, an approach that has been validated by our group in prior research [65]. A comment field is also available where additional information can be added using free text. The list of prescribed and discontinued medications will be printed, signed by the attending physician or resident, and a copy printed and retained for the chart.

For each discontinued medication or dose change, the dispensing pharmacy and prescribing physician will be identified from the community-based pharmacy claim record. The identity of the prescribing physician and pharmacy must be completed accurately for the pharmacy to receive payment from the RAMQ. Access to this information has been approved for this study by the provincial privacy commission. For each discontinued drug, the name of the patient and drug, the reason for discontinuation, the attending physician, the hospital

and the discharge date will be faxed to the respective dispensing pharmacy and prescribing physician.

Outcome assessment

Adverse drug events

An ADE is defined as an injury resulting from medical intervention related to a drug [1,7]. ADEs will be assessed by collecting self-reported patient information 30 days post-discharge; retrieving chart and administrative data on drugs that were started, stopped or continued at discharge as well as acute and chronic health problems; and reviewing and adjudicating the presence of an adverse event and the probability of it being drug-related by a blinded expert panel review of each patient's chart and post-discharge interview data, using two approaches. The Leape and Bates approach will also be used to assess whether an injury resulting from a drug-related medical intervention occurred, and its severity and preventability [1,7,74]. The Leape and Bates approach will include injuries related to both failing to restart a drug that was held at admission for an elective surgical procedure and injuries caused by unplanned

Discharge Communication Module

Please select a reason for changing the dose:

Atorvastatin 20mg PO qHS	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hydrochlorothiazide 12.5mg PO qD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lorazepam 0.5mg PO qHS PRN	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please select a reason for stopping:

Codeine 30mg PO q4h PRN	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Diclofenac 1.5% to Right knee bid	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Glimepiride 5mg PO qD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Heparin 5000U S/C q12h	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lisinopril 20mg PO qD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Metformin 850mg PO tid with meals	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Omeprazole 20mg PO qD	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rosiglitazone 8mg PO qAM	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Salbutamol 1 neb aerosol q6h PRN	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Prescribed

Bisoprolol 5mg PO bid	NTG spray 0.4mg S/L PRN
Cal-D 1 PO bid	Perindopril 2mg PO qAM
Clopidrogel 75mg PO qD	Risedronate 35mg PO qSundays
ECASA 81mg PO qD	Salinex 2 spray qid PRN
Glucalazide 40mg PO bid	Tylenol 500mg bid PRN
Ibuprofen 200mg PO tid	Vitamin B12 100mcg IM qMonth
Levothyroxine 0.1mg PO qD	
Mometasone 50mcg Nasal spray 2 sprays qD	

Print/Fax to:

<input checked="" type="checkbox"/>	Dr Madeleine Houde	Pharmacie Hébert Ferlatte Pharmaciens Inc.
<input checked="" type="checkbox"/>	Dr Yves Bédard	Familiprix André Guimond Pharmacien

Print/Fax to:

<input checked="" type="checkbox"/>	Dr Madeleine Houde	Pharmacie Hébert Ferlatte Pharmaciens Inc.
<input checked="" type="checkbox"/>	Dr Bertha Fuchsman	Jean Coutu # 123 Claude Lachance
<input checked="" type="checkbox"/>	Dr Madeleine Houde	Pharmacie Hébert Ferlatte Pharmaciens Inc.
<input checked="" type="checkbox"/>	Dr Yves Bédard	Familiprix André Guimond Pharmacien
<input checked="" type="checkbox"/>	Dr Madeleine Houde	Pharmacie Hébert Ferlatte Pharmaciens Inc.
<input checked="" type="checkbox"/>	Dr Yves Bédard	Familiprix André Guimond Pharmacien

Back

Proceed

Figure 4 Discharge communication module.

duplications of therapy when changes in treatment occur in hospital without notifying community physicians and pharmacists. The Naranjo criteria [75] will also be used to assess the probability that an event was attributable to a specific drug (that was newly started, changed or continued during hospitalization).

Self-report interview

Patient self-report will be used because it is the most sensitive method of ADE detection, identifying an additional 28% of adverse events compared with medical chart review, of which 13% are considered serious [76]. A modification of the Australian two-step adverse reaction and drug event report will be administered by telephone to solicit patient feedback on potential adverse events and their characteristics [77]. In the first step, patients will be asked to report any new health problem or change in their condition since discharge. In the second step, a review of systems is conducted using directed probes for changes in systems-related symptoms or signs that may be drug-related (for example, skin rash, cough). For positive responses, patients will be asked to describe each new problem, and indicate when it started in relation to the initiation, change or termination of drug treatment post-discharge. Most adverse events occur early in the post-discharge period; therefore, we will conduct the follow-up interview in the first 25 to 30 days [7,36]. A trained research assistant will conduct patient follow-up interviews, blinded to intervention status.

Chart abstraction

A trained nurse abstractor, blinded to intervention status, will abstract the medical chart data for each patient. Health problems will be coded using the International Classification of Diseases (ICD)-10, medications by generic chemical code using the Anatomic-Therapeutic Classification system, and procedures by the Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (CCP). Data will be entered using the MOXXI chart abstraction system as it permits text entries (for example, hydrochlorothiazide 10 mg, rheumatoid arthritis) to be mapped to the respective classification system, and stored by patient identifier in the MOXXI Oracle database. A case summary record that includes the community drug list, hospital drug list, discharge abstract, discharge medications and patient self-report will be prepared for assessment by the expert panel.

Expert review and adverse drug events assessment

The chart abstraction case summary and patient self-report interview report will be reviewed independently by three clinicians. Clinicians will be blinded to the

patient's intervention status (usual care versus discharge reconciliation).

First, each clinician will use the Leape-Bates classification system [1,7] to assess whether an ADE was present (yes, no), and its severity into one of four mutually exclusive categories (fatal, life-threatening, serious, significant). Each clinician will also be asked to judge if an event was preventable, based on currently available means, using a four-category Likert scale (definitely preventable, probably preventable, probably not preventable, definitely not preventable). Each clinician will also be asked to note the most likely contributing causes to the event. Inter-clinician agreement is reported to be excellent for judging occurrence ($k = 0.98$) and preventability ($k = 0.92$), and moderate for assessing severity ($k = 0.32$ to 0.37) [1,7].

Second, each clinician will assess the probability that new symptoms or problems occurring post-discharge are related to any one of the drugs that were started, changed or continued at discharge using the Naranjo criteria. The Naranjo criteria for ADE assessment is the most widely used method of adverse drug reaction causality assessment [78]. The Naranjo instrument uses the presence or absence of 10 criteria to assess whether a drug is the cause of an adverse event (for example, renal failure). The relative importance of each criterion is weighted from -1 to $+2$. The sum of criteria-specific weights is used to classify the probability that the event was drug-related into one of four categories: definite (score ≥ 9), probable (score 5 to 8), possible (score 1 to 4) or doubtful (score ≤ 0) [75]. Inter-rater agreement in assessing events using the Naranjo criteria is good to excellent ($k = 0.69$ to 0.86). Gold standard ADEs will be defined as those with a causality assessment score classified as definite or probable.

After independent rating, all patient cases will be reviewed and discussed by the panel of three clinicians to reach a consensus classification for both the Leape-Bates classification and Naranjo. We will test inter-rater agreement using 10 training charts before the start of the study, and each month during follow-up using one standardized chart per month. Agreement in scoring on the training and monthly quality control charts will be assessed by an intra-class correlation and by weighted kappa.

Emergency department visit or hospital readmission

As a secondary outcome, we will include all visits to the ED or hospital readmission in the 30 days post-discharge, measured using the RAMQ provincial health care databases. This approach ensures that all ED visits and readmissions are included, not just those occurring at the McGill University Health Centre. This is important because ambulances will transport individuals to the

closest, open ED or hospital, which often is not the discharging institution. Almost all hospital-based physicians in Quebec are remunerated on a fee-for-service basis [79], and for each medical service delivered, physicians are required to accurately record the treating establishment, and the location of the service (for example, intensive care unit, ED, day hospital, inpatient unit), because location and type of establishment determine the level of remuneration. For each consenting patient, the RAMQ will retrieve all records of services provided in the month after discharge. Patients will be classified as having an ED visit if they have a record of service with a location of a hospital ED, and a readmission if they have a service delivered from an inpatient general hospital unit. In secondary analysis, we will retrieve all ICD-10 diagnostic codes recorded for ED visits and readmissions to provide descriptive information on potential reasons for the visit or readmission.

Randomization

The 26 hospital units will be assigned a random number, stratified by type (medicine, surgery), and the default random number generator in Statistical Analysis Software (SAS) will be used to randomly assign units within stratum to electronically enabled discharge reconciliation or usual care. There will be approximately 1,857 patients assigned to medication reconciliation at discharge and 1,857 to usual care.

Sample size

We based our sample size requirements on the difference in the rate of ADEs, as this binary outcome with correlated patient observations required the maximum sample size. For this outcome, we bracketed expected rates of ADEs in the control group based on recent Canadian and US studies [4,5,7] to be between 10% and 19%. We specified an absolute reduction of 5% as the smallest clinically relevant difference that would be worthwhile to detect. A difference of this magnitude would conservatively result in 96,000 fewer ADEs in Canada annually, at an estimated annual cost-saving of \$240 million [3]. Specifying an acceptable Type 1 error of 5%, and Type 2 error of 20%, the estimated sample size for the expected range in possible cluster correlations ($r = 0.02$ to 0.05) varies from 2,852 to 4,423 patient admissions, assuming a baseline rate in the control group of 15% (midway between 10% and 19%). Based on an analysis of readmission rates in 2008, a cluster correlation no greater than 0.03 is expected, which would mean a sample size of 3,376 is required to detect a 5% reduction in ADEs. Based on our prior work, we estimate that 10% of patients will not be reached to complete the post-discharge follow-up interview [4,5]; therefore, we estimate that we will need to recruit 3,714

patients to achieve our sample size requirements. Overall, in 2008, there were 17,480 admissions to the McGill University Health Centre, of which 12,236 were admitted to eligible medical and surgical units. Based on our pilot study, approximately 42% ($n = 5,139$) of patients will be eligible for inclusion (that is, have public drug insurance, ≥ 18 years old, first admission in study period, alive at discharge), and of these 3% will refuse to participate, 45% will not be asked for consent because the staff are too busy, and 52% will consent to participate. By providing staff with support to obtain consent from patients, we expect that we can increase the proportion of eligible patients participating to 60%, or 257 per month. Assuming 10 months per year of active recruitment (to account for summer and winter holidays), we estimate that it will take 15 months to recruit all patients. With an average length of stay of 8.9 days, we should successfully complete enrolment and follow-up in 18 to 20 months.

Data management and analysis

Four sources of data will be assembled and linked to address the study objective: abstracted medical chart documentation of patient demographics, admission and discharge dates, the community drug list, discharge prescription, and admitting and discharge diagnoses; adverse events information and assessment post-discharge; the RAMQ medical services and prescription claims data; and co-intervention data collected by the study coordinator. All data will be managed in an Oracle database, and files for individual patients will be linkable through a study identification number and Quebec medicare number, with nominal information retained in a separate encrypted file. The integrity of randomization will be assessed by characterizing the age, sex, baseline number of visits, hospitalizations, medications, and comorbidity of patients using the Charlson comorbidity index, a weighted index of conditions that increase the risk of mortality [80]. The CONSORT guidelines will be followed to document the eligibility and follow-up of patients and inpatient units (clusters) in the trial [81]. Provincial health administrative data will be used to characterize bias related to patients lost to follow-up after discharge for whom ADEs cannot be measured, based on the secondary outcome (readmission or ED visits).

An intention-to-treat approach will be used to analyse study results. To determine whether discharge reconciliation reduces the risk of ADEs post-discharge, we will use logistic regression within a generalized estimating equation framework to account for clustering of patients within unit [82]. The presence of an ADE (either identified as present based on the Leape-Bates classification or Naranjo criteria) will be the outcome variable, the hospital unit will be the defined clustering factor, and an

exchangeable correlation matrix will be used to account for clustering of patients within unit. Discharge reconciliation will be fit as a dummy variable, using usual care as the reference group. We will use the same approach to assess the secondary outcome, ED visits or hospital readmission. For both the primary and secondary outcome, we will assess whether adjustment for co-interventions and baseline differences between patients in the usual care and intervention arm confound the effect of the intervention. In a secondary analysis, we will assess whether the effect of the intervention is modified by hospital unit type (medicine versus surgery) or patient characteristics that are associated with a higher risk of adverse events (age, number of medications at discharge) by including respective interaction terms in the logistic model and testing their significance using the Wald chi-square statistic.

Bias and blinding

Our main challenge in bias control is the inability to blind staff to treatment assignment, and potential co-intervention. To control bias, the research assistant, expert panel and analyst assessing the outcome of treatment will be blinded to unit and treatment allocation status. To assess bias related to possible co-interventions, the project coordinator will conduct a monthly review with the unit directors and hospital pharmacy to assess co-interventions (new initiatives that may modify the study outcomes), and we will use sensitivity analysis to assess the potential impact on the study outcomes. As the involvement of the hospital pharmacist in the patient's care likely reduces the risk of adverse events (for example, through medication review), we will retrieve this information from the chart and assess whether hospital pharmacist intervention (yes versus no) is a confounder by including this information as a patient-level variable in the analysis. In addition, as cluster randomization may not produce patients groups who have an equivalent risk of adverse events post-discharge (that is, because randomization is by unit rather than by patient), we will assess whether patients admitted to the usual care versus electronically enabled discharge units had a similar rate of hospitalizations, and ED visits in the 12 months prior to admission using RAMQ medical service data retrieved for each patient. In addition, we will include prior ED or hospitalization history in the analysis to determine if it confounds the estimated effect of the intervention.

Ethical considerations

This study received full board review from the McGill University Health Centre Research Ethics Board and was found ethically acceptable for conduct on March 9 2011.

To monitor any unintended adverse effects arising from the study intervention(s), we will establish an

independent data monitoring board, chaired by Dr David Bates (Harvard University), and including Dr Gordon Schiff (Harvard University) and Dr Anne Holbrook (McMaster University), scientists who provide pre-eminent expertise in ADEs and computerization of health care. The data monitoring board will monitor quarterly statistics on hospital readmission and ED visit rates to assess unintended effects, blinded to study group. The study team will be responsible for providing any additional statistical information that is deemed necessary by the data monitoring board to ensure patient safety.

Discussion

A major challenge in this study will be to ensure that attending physicians or residents have sufficient training, motivation and support to use the medication reconciliation module for the discharge prescription. The four conditions needed for successful adoption will be incorporated into the implementation of discharge reconciliation [83]. First, we will train local leadership within each unit to champion the discharge reconciliation process, comprising the unit service chief, head nurse and liaison pharmacist. Second, we will pre-test and calibrate the user interface to minimize workflow disruption and maximize efficiency gains. Based on our experience of instituting electronic prescribing in the primary care setting, we expect that we can save three or more minutes per discharge prescription by allowing relevant hospital and community-based prescriptions to be copied to the discharge prescription [68]. Third, we will prepare, with the clinical champions, a blitz launch in each unit that will feature onsite support for completing the discharge prescription in each unit for the first two weeks. We have successfully used nursing and medical students, who are typically adept computer users, to provide real-time coaching and support for using new clinical computer applications. Last, we will monitor adoption by using application audit trails, and use this information to identify and remedy problems that may exist on certain units.

Medication reconciliation at hospital discharge is expected to reduce unintended discrepancies in community- and hospital-based treatment, and minimize preventable ADEs. We expect that the intervention evaluated in this trial may improve adherence to medication reconciliation at discharge, the accuracy of the community drug history, and effective communication of hospital-based treatment changes to community-based care providers. The solutions we will test are available in all Canadian provinces and many other countries, and made accessible to hospital- and community-based care teams. If we find that the intervention reduces ADEs, it will support policy-directed quality investments in computerization and training hospital staff to use

pharmacy-based records and a discharge reconciliation module to improve medication reconciliation. It will also generate key requirements for medication reconciliation that can be applied in future hospital accreditation standards, as well as highlight functional requirements for software vendors.

Trial status

Anticipated start date: September 2012.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RT, AH, AF, AM, NW, AJ, CR and DB conceived of the study and participated in its design and oversight. KN and KR participated in coordination and interpretation of results, as well as manuscript writing. All authors read and approved the final version of the manuscript.

Author details

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada. ²Clinical and Health Informatics Research Group, McGill University, 1140 Pine Avenue West, Montreal, QC H3A 1A3, Canada. ³Department of Medicine, Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Room A3.09, Montreal, QC H3A 1A1, Canada. ⁴Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, ON K1Y 4E9, Canada. ⁵Collège des Médecins du Québec, 2170 René-Lévesque Boulevard West, Montreal, QC H3H 2T8, Canada.

Received: 14 December 2011 Accepted: 7 August 2012

Published: 27 August 2012

References

- Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, Vander Vliet M, Nemeskal R, Leape LL, Hojnowski-Diaz P, Petrycki S, Cotugno M, Patterson H, Hickey M, Kleefield S, Cooper J, Cullen DJ, Kinneally E, Demonaco HJ, Dempsey Clapp M, Gallivan T, Ives J, Porter K, Thompson T, Hackman R, Edmonson A: **Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.** *JAMA* 1995, **274**:29–34.
- Lazarou J, Pomeranz BH, Corey PN: **Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.** *JAMA* 1998, **279**:1200–1205.
- Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA: **The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.** *JAMA* 1997, **277**:307–311.
- Forster AJ, Clark HD, Menard A, Dupuis N, Chernish R, Chandok N, Khan A, van Walraven C: **Adverse events among medical patients after discharge from hospital.** *CMAJ* 2004, **170**:345–349.
- Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW: **The incidence and severity of adverse events affecting patients after discharge from the hospital.** *Ann Intern Med* 2003, **138**:161–167.
- Coleman EA, Smith JD, Raha D, Min SJ: **Posthospital medication discrepancies: prevalence and contributing factors.** *Arch Intern Med* 2005, **165**:1842–1847.
- Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, Hallisey R, Ives J, Laird N, Laffel G, Nemeskal R, Petersen LA, Porter K, Servi D, Shea BF, Small SD, Sweitzer BJ, Thompson T, Vander Vliet M, Hojnowski-Diaz P, Petrycki S, Cotugno M, Patterson H, Hickey M, Kleefield S, Kinneally E, Dempsey Clapp M, Hackman R, Edmonson A: **Systems analysis of adverse drug events. ADE Prevention Study Group.** *JAMA* 1995, **274**:35–43.
- Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, Urbach DR: **Potentially unintended discontinuation of long-term medication use after elective surgical procedures.** *Arch Intern Med* 2006, **166**:2525–2531.
- Bell CM, Brenner SS, Gunraj N, Huo C, Bierman AS, Scales DC, Bajcar J, Zwarenstein M, Urbach DR: **Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases.** *JAMA* 2011, **306**:840–847.
- Paparella S: **Medication reconciliation: doing what's right for safe patient care.** *J Emerg Nurs* 2006, **32**:516–520.
- Using medication reconciliation to prevent errors. *Jt Comm J Qual Patient Saf* 2006, **32**:230–232.
- Saufl NM: **Reconciliation of medications.** *J Perianesth Nurs* 2006, **21**:126–127.
- Manno MS, Hayes DD: **Best-practice interventions: how medication reconciliation saves lives.** *Nursing* 2006, **36**:63–64.
- Vira T, Colquhoun M, Etchells E: **Reconcilable differences: correcting medication errors at hospital admission and discharge.** *Qual Saf Health Care* 2006, **15**:122–126.
- Barker KN, Flynn EA, Pepper GA, Bates DW, Mikeal RL: **Medication errors observed in 36 health care facilities.** *Arch Intern Med* 2002, **162**:1897–1903.
- Kemp LO, Narula P, McPherson ML, Zuckerman I: **Medication reconciliation in hospice: a pilot study.** *Am J Hosp Palliat Care* 2009, **26**:193–199.
- Ledger S, Choma G: **Medication reconciliation in hemodialysis patients.** *CANN J* 2008, **18**:41–43.
- Gleason KM, Groszek JM, Sullivan C, Rooney D, Barnard C, Noskin GA: **Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients.** *Am J Health Syst Pharm* 2004, **61**:1689–1695.
- Vigoda MM, Gencorelli FJ, Lubarsky DA: **Discrepancies in medication entries between anesthetic and pharmacy records using electronic databases.** *Anesth Analg* 2007, **105**:1061–1065.
- Weingart SN, Cleary A, Seger A, Eng TK, Saadeh M, Gross A, Shulman LN: **Medication reconciliation in ambulatory oncology.** *Jt Comm J Qual Patient Saf* 2007, **33**:750–757.
- Groeschel H: **Electronic system improves medication reconciliation rates.** *Am J Health Syst Pharm* 1994, **2007**:64.
- What's expected for med reconciliation? *OR Manager* 2008, **24**(3):21–23.
- Rozich JD, Howard RJ, Justeson JM, Macken PD, Lindsay ME, Resar RK: **Standardization as a mechanism to improve safety in health care.** *Jt Comm J Qual Saf* 2004, **30**:5–14.
- Bridgeman PJ, Rynn KO: **Medication reconciliation in the emergency department.** *Am J Health Syst Pharm* 2008, **65**(24):2325–2326.
- Meds reconciliation summit promises more clarification: **Meds reconciliation summit promises more clarification.** *ED Manag* 2008, **20**(2): suppl 3–4.
- Agrawal A, Wu WY: **Reducing medication errors and improving systems reliability using an electronic medication reconciliation system.** *Jt Comm J Qual Patient Saf* 2009, **35**:106–114.
- Lesselroth BJ, Felder RS, Adams SM, Cauthers PD, Dorra DA, Wong GJ, Douglas DM: **Design and implementation of a medication reconciliation kiosk: the Automated Patient History Intake Device (APHID).** *J Am Med Inform Assoc* 2009, **16**(3):300–304.
- Akwagiyam I, Goodyer LI, Harding L, Khakoo S, Millington H: **Drug history taking and the identification of drug related problems in an accident and emergency department.** *J Accid Emerg Med* 1996, **13**:166–168.
- Lau HS, Florax C, Porsius AJ, De BA: **The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards.** *Br J Clin Pharmacol* 2000, **49**:597–603.
- Poon EG, Blumenfeld B, Hamann C, Turchin A, Graydon-Baker E, McCarthy PC, Poikonen J, Mar P, Schnipper JL, Hallisey RK, Smith S, McCormack C, Paterno M, Coley CM, Karson A, Chueh HC, Van Putten C, Millar SG, Clapp M, Bhan I, Meyer GS, Gandhi TK, Broverman CA: **Design and implementation of an application and associated services to support interdisciplinary medication reconciliation efforts at an integrated healthcare delivery network.** *J Am Med Inform Assoc* 2006, **13**:581–592.
- Turchin A, Hamann C, Schnipper JL, Graydon-Baker E, Millar SG, McCarthy PC, Coley CM, Gandhi TK, Broverman CA: **Evaluation of an inpatient computerized medication reconciliation system.** *J Am Med Inform Assoc* 2008, **15**:449–452.
- Clay BJ, Halasyamani L, Stucky ER, Greenwald JL, Williams MV: **Results of a medication reconciliation survey from the 2006 Society of Hospital Medicine national meeting.** *J Hosp Med* 2008, **3**:465–472.
- Tam VC, Knowles SR, Cornish PL, Fine N, Marchesano R, Etchells EE: **Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review.** *CMAJ* 2005, **173**:510–515.
- Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN,

- Juurlink DN, Etchells EE: **Unintended medication discrepancies at the time of hospital admission.** *Arch Intern Med* 2005, **165**:424-429.
35. LaPointe NM, Jollis JG: **Medication errors in hospitalized cardiovascular patients.** *Arch Intern Med* 2003, **163**:1461-1466.
36. Pippins JR, Gandhi TK, Hamann C, Ndumele CD, Labonville SA, Diedrichsen EK, Carty MG, Karson AS, Bhan I, Coley CM, Liang CL, Turchin A, McCarthy PC, Schnipper JL: **Classifying and predicting errors of inpatient medication reconciliation.** *J Gen Intern Med* 2008, **23**:1414-1422.
37. Mersfelder TL, Bickel RJ: **Inpatient medication history verification by pharmacy students.** *Am J Health Syst Pharm* 2008, **65**:2273-2275.
38. Miller SL, Miller S, Balon J, Helling TS: **Medication reconciliation in a rural trauma population.** *Ann Emerg Med* 2008, **52**:483-491.
39. van den Bemt PM, van den BS, van Nunen AK, Harbers JB, Lenderink AW: **Medication reconciliation performed by pharmacy technicians at the time of preoperative screening.** *Ann Pharmacother* 2009, **43**:868-874.
40. Lubowski TJ, Cronin LM, Pavelka RW, Briscoe-Dwyer LA, Briceland LL, Hamilton RA: **Effectiveness of a medication reconciliation project conducted by PharmD students.** *Am J Pharm Educ* 2007, **71**:94.
41. Schwarz M, Wyskiel R: **Medication reconciliation: developing and implementing a program.** *Crit Care Nurs Clin North Am* 2006, **18**:503-507.
42. Haig K: **Medication reconciliation.** *Am J Med Qual* 2006, **21**:299-303.
43. Bayley KB, Savitz LA, Maddalone T, Stoner SE, Hunt JS, Wells R: **Evaluation of patient care interventions and recommendations by a transitional care pharmacist.** *Ther Clin Risk Manag* 2007, **3**:695-703.
44. Varkey P, Resar RK: **Medication reconciliation implementation in an academic center.** *Am J Med Qual* 2006, **21**:293-295.
45. Kramer JS, Hopkins PJ, Rosendale JC, Garrelts JC, Hale LS, Nester TM, Cochran P, Eidem LA, Haneke RD: **Implementation of an electronic system for medication reconciliation.** *Am J Health Syst Pharm* 2007, **64**:404-422.
46. McGill Calgary Drug Research Team, Isaac LM, Tamblyn RM: **Compliance and cognitive function: a methodological approach to measuring unintentional errors in medication compliance in the elderly.** *Gerontologist* 1993, **33**(6):772-781.
47. Karnon J, Campbell F, Czosi-Murray C: **Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation).** *J Eval Clin Pract* 2009, **15**:299-306.
48. Orrico KB: **Sources and types of discrepancies between electronic medical records and actual outpatient medication use.** *J Manag Care Pharm* 2008, **14**:626-631.
49. Fulford MD, Berger BA, Newton DS: **The relationship between computerization and profitability in independent community pharmacies.** *J Pharm Mark Manag* 1988, **3**:75-98.
50. Sikka R, Xia F, Aubert RE: **Estimating medication persistency using administrative claims data.** *Am J Manag Care* 2005, **11**:449-457.
51. Steiner JF, Prochazka AV: **The assessment of refill compliance using pharmacy records: methods, validity, and applications.** *J Clin Epidemiol* 1997, **50**:105-116.
52. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R: **Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.** *Med Care* 1999, **37**:846-857.
53. Bails D, Clayton K, Roy K, Cantor MN: **Implementing online medication reconciliation at a large academic medical center.** *Jt Comm J Qual Patient Saf* 2008, **34**:499-508.
54. Schenkel S: **The unexpected challenges of accurate medication reconciliation.** *Ann Emerg Med* 2008, **52**:493-495.
55. Aarts J, Koppel R: **Implementation of computerized physician order entry in seven countries.** *Health Aff* 2009, **28**(2):404-414.
56. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS: **Physicians' decisions to override computerized drug alerts in primary care.** *Arch Intern Med* 2003, **163**:2625-2631.
57. Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G, Grad R, Jacques A, Dawes M, Abrahamowicz M, Perreault R, Winslade N, Poissant L, Pinsonneault A: **A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care.** *J Am Med Inform Assoc* 2008, **15**:430-438.
58. Beers MH, Dang J, Hasegawa J, Tamai IY: **Influence of hospitalization on drug therapy in the elderly.** *J Am Geriatr Soc* 1989, **37**:679-683.
59. Jackevicius CA, Paterson JM, Naglie G: **Concordance between discharge prescriptions and insurance claims in post-myocardial infarction patients.** *Pharmacoevidenc Drug Saf* 2007, **16**:207-215.
60. Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM, Johnson AE, Forsythe SR, O'Donnell JK, Paasche-Orlow MK, Manasseh C, Martin S, Culpepper L: **A reengineered hospital discharge program to decrease rehospitalization.** *Ann Intern Med* 2009, **150**:178-187.
61. Tamblyn RM, McLeod P, Abrahamowicz M, Berkson L, Dauphinee D, Gayton D, et al: **Multi-Physician Involvement and Questionable High Risk Prescribing in the Elderly.** Toronto: The Canadian Pharmacoevidenc Forum; 1993.
62. Tamblyn RM: **Improving patient safety through computerized drug management: The devil is in the details.** *HealthCare Papers* 2004, **5**:52-68.
63. Kanjanarat P, Winterstein AG, Johns TE, Hattton RC, Gonzalez-Rothi R, Segal R: **Nature of preventable adverse drug events in hospitals: a literature review.** *Am J Health Syst Pharm* 2003, **60**:1750-1759.
64. Members of EMERGE, Erice Medication Errors Research Group, Agrawal A, Aronson JK, Britten N, Ferner RE, de Smet PA, Fialova D, Fitzgerald RJ, Likić R, Maxwell SR, Meyboom RH, Minuz P, Onder G, Schachter M, Velo G: **Medication errors: problems and recommendations from a consensus meeting.** *Br J Clin Pharmacol* 2009, **67**:592-598.
65. Egualte T, Tamblyn R, Winslade N, Buckeridge D: **Detection of adverse drug events and other treatment outcomes using an electronic prescribing system.** *Drug Saf* 2008, **31**:1005-1016.
66. Kawasumi Y, Tamblyn R, Platt R, Ernst P, Abrahamowicz M, Taylor L: **Evaluation of the use of an integrated drug information system by primary care physicians for vulnerable population.** *Int J Med Inform* 2008, **77**:98-106.
67. Taylor LK, Kawasumi Y, Bartlett G, Tamblyn R: **Inappropriate prescribing practices: the challenge and opportunity for patient safety.** *Healthc Q* 2005, **8**:81-85.
68. Tamblyn R, Huang A, Kawasumi Y, Bartlett-Esquiland G, Grad R, Jacques A, Dawes M, Abrahamowicz M, Perreault R, Taylor L, Winslade N, Poissant L, Pinsonneault A: **The development and evaluation of an integrated electronic prescribing and drug management system for primary care.** *J Am Med Inform Assoc* 2006, **13**:148-159.
69. Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, McLeod P, Laprise R: **The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care.** *CMAJ* 2003, **169**:549-556.
70. Bartlett G, Blais R, Tamblyn R, Clermont RJ, MacGibbon B: **Impact of patient communication problems on the risk of preventable adverse events in acute care settings.** *CMAJ* 2008, **178**:1555-1562.
71. Interagency Advisory Panel on Research Ethics: **Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.** Ottawa: Interagency Secretariat on Research Ethics; 2008:1-154.
72. Tamblyn RM, Lavoie G, Petrella L, Monette J: **The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec.** *J Clin Epidemiol* 1995, **48**(8):999-1009.
73. Kawasumi Y, Abrahamowicz M, Ernst P, Tamblyn R: **Development and validation of a predictive algorithm to identify adult asthmatics from medical services and pharmacy claims databases.** *Health Serv Res* 2011, **46**:939-963.
74. Nebeker JR, Barach P, Samore MH: **Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting.** *Ann Intern Med* 2004, **140**:795-801.
75. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: **A method for estimating the probability of adverse drug reactions.** *Clin Pharmacol Ther* 1981, **30**:239-245.
76. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW: **Adverse drug events in ambulatory care.** *N Engl J Med* 2003, **348**:1556-1564.
77. Mitchell AS, Henry DA, Hennrikus D, O'Connell DL: **Adverse drug reactions: can consumers provide early warning?** *Pharmacoevidenc Drug Saf* 1994, **3**:257-264.
78. Kelly WN: **The quality of published adverse drug event reports.** *Ann Pharmacother* 2003, **37**:1774-1778.
79. Regie de l'assurance-maladie du Quebec: **Statistiques Annuelles.** Quebec: Regie de l'assurance-maladie du Quebec; 2000:46-48.
80. Charlson ME, Pompei P, Ales KL, MacKenzie CR: **A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.** *J Chronic Dis* 1987, **40**(5):373-383.
81. Campbell MK, Elbourne DR, Altman DG: **CONSORT statement: extension to cluster randomised trials.** *Br Med J* 2004, **328**:702-708.

82. Zeger SL, Liang KY, Albert PS: **Models for longitudinal data: a generalized estimating equation approach.** *Biometrics* 1988, **44**:1049–1060.
83. Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, Spurr C, Khorasani R, Tanasijevic M, Middleton B: **Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality.** *J Am Med Inform Assoc* 2003, **10**:523–530.

doi:10.1186/1745-6215-13-150

Cite this article as: Tamblyn *et al.*: Using novel Canadian resources to improve medication reconciliation at discharge: study protocol for a randomized controlled trial. *Trials* 2012 **13**:150.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

